MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

Merck's pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), met its primary endpoint in the Phase III HYPERION study, demonstrating a statistically significant and clinically meaningful reduction in clinical worsening events in newly diagnosed intermediate or high-risk PAH patients. This marks the third successful Phase III trial for Winrevair, bolstering its commercial outlook. Approved in March 2024, Winrevair generated $280 million in Q1 2025 sales and is strategically vital for Merck to offset the anticipated patent expiry of its blockbuster drug Keytruda in 2028, positioning it as a key long-term revenue driver.

Analysis

Merck has significantly de-risked the outlook for its pulmonary arterial hypertension (PAH) drug, Winrevair, following the successful conclusion of the Phase III HYPERION study. This marks the third positive Phase III trial for the drug, with the study being stopped early due to overwhelming efficacy, reinforcing its strong clinical profile. The commercial launch is already demonstrating significant momentum, with Winrevair generating $280 million in sales in the first quarter of 2025, a 40% sequential increase. This performance is critical for Merck's long-term strategy, as the company is positioning Winrevair as a key revenue driver to offset the patent expiration of its blockbuster drug, Keytruda, in 2028. Despite this positive catalyst, Merck's stock has underperformed, declining 19.4% year-to-date against an industry decrease of 2.6%. Winrevair is entering a competitive market dominated by established players like Johnson & Johnson, whose PAH franchise posted $1.02 billion in Q1 2025 revenue, and United Therapeutics, with its portfolio generating over $725 million in the same period.

Key Decisions for Investors

• The consistent positive Phase III data and strong initial sales of Winrevair validate it as a credible long-term growth asset, strengthening the bull case for Merck's ability to navigate the upcoming Keytruda patent cliff.
• Investors should closely monitor Winrevair's prescription trends and market share gains against incumbents Johnson & Johnson and United Therapeutics to gauge its potential to become a multi-billion dollar product.
• Given the disconnect between Merck's significant stock underperformance year-to-date and the positive fundamental developments for Winrevair, current valuation levels may present an attractive entry point for investors with a long-term horizon.